Toll-like receptor therapies compete to reduce side effects.
Schmidt
Charlie
C
D006801:Humans; D007113:Immunity, Innate; D007155:Immunologic Factors / Q000378:metabolism*; D007167:Immunotherapy / Q000009:adverse effects*; D009369:Neoplasms / Q000628:therapy; D051193:Toll-Like Receptors / Q000378:metabolism / Q000627:therapeutic use*
D007155:Immunologic Factors; D051193:Toll-Like Receptors